公开(公告)号：US20180369249A1

公开(公告)日：2018-12-27

申请号：US16075202

申请日：2017-02-03

申请人： Academia Sinica ,  National Taiwan University

发明人： Chi-Huey Wong ,  Pan-Chyr Yang ,  Jim-Min Fang ,  Szu-Hua Pan ,  Ting-Jen R. Cheng ,  Ling-Wei Li

IPC分类号： A61K31/522 ,  A61K35/00

摘要： The present disclosure provides compounds of Formulas (I′) and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases.

公开(公告)号：US10765681B2

公开(公告)日：2020-09-08

申请号：US16075202

申请日：2017-02-03

申请人： Academia Sinica ,  National Taiwan University

发明人： Chi-Huey Wong ,  Pan-Chyr Yang ,  Jim-Min Fang ,  Szu-Hua Pan ,  Ting-Jen R. Cheng ,  Ling-Wei Li

IPC分类号： C07D473/00 ,  A61K31/522 ,  A61K45/06 ,  A61K31/337 ,  A61K31/52 ,  A61K31/506 ,  A61K31/502 ,  A61K31/167 ,  A61K31/454 ,  A61K38/05 ,  A61K31/517 ,  A61K31/4025 ,  A61K31/5377 ,  A61K31/69 ,  A61K31/44 ,  A61K35/00

摘要： The present disclosure provides compounds of Formulas (I′) and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases.

公开(公告)号：US20200095233A1

公开(公告)日：2020-03-26

申请号：US16081490

申请日：2017-02-28

申请人： Academia Sinica ,  National Taiwan University

发明人： Chi-Huey Wong ,  Pan-Chyr Yang ,  Rong-Jie Chein ,  Szu-Hua Pan ,  Ting-Jen R. Cheng

IPC分类号： C07D405/12 ,  C07D413/12 ,  C07D307/92 ,  C07D403/12

摘要： The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).

公开(公告)号：US11919886B2

公开(公告)日：2024-03-05

申请号：US17811880

申请日：2022-07-12

申请人： Academia Sinica ,  National Taiwan University

发明人： Chi-Huey Wong ,  Pan-Chyr Yang ,  Rong-Jie Chein ,  Szu-Hua Pan ,  Ting-Jen R. Cheng

IPC分类号： A61K31/4025 ,  A61K31/4178 ,  C07D307/92 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

CPC分类号： C07D405/12 ,  A61K31/4025 ,  A61K31/4178 ,  C07D307/92 ,  C07D403/12 ,  C07D413/12

摘要： The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).

公开(公告)号：US20230010562A1

公开(公告)日：2023-01-12

申请号：US17811880

申请日：2022-07-12

申请人： Academia Sinica ,  National Taiwan University

发明人： Chi-Huey Wong ,  Pan-Chyr Yang ,  Rong-Jie Chein ,  Szu-Hua Pan ,  Ting-Jen R. Cheng

IPC分类号： C07D405/12 ,  C07D307/92 ,  C07D403/12 ,  C07D413/12

摘要： The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).

公开(公告)号：US11434229B2

公开(公告)日：2022-09-06

申请号：US16081490

申请日：2017-02-28

申请人： Academia Sinica ,  National Taiwan University

发明人： Chi-Huey Wong ,  Pan-Chyr Yang ,  Rong-Jie Chein ,  Szu-Hua Pan ,  Ting-Jen R. Cheng

IPC分类号： C07D405/12 ,  C07D307/92 ,  C07D403/12 ,  C07D413/12

摘要： The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).

公开(公告)号：US11992525B2

公开(公告)日：2024-05-28

申请号：US18501578

申请日：2023-11-03

申请人： ACADEMIA SINICA

发明人： Chi-Huey Wong ,  Hsin-Yu Liao ,  Shih-Chi Wang ,  Yi-An Ko ,  Kuo-I Lin ,  Che Ma ,  Ting-Jen Cheng

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61P31/16 ,  C07K14/005

CPC分类号： A61K39/145 ,  A61P31/16 ,  C07K14/005 ,  A61K2039/575

摘要： The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

公开(公告)号：US11866485B2

公开(公告)日：2024-01-09

申请号：US17937744

申请日：2022-10-03

申请人： ACADEMIA SINICA

发明人： Kuo-I Lin ,  Che Ma ,  Chi-Huey Wong ,  Szu-Wen Wang ,  Yi-Hsuan Chang ,  Xiaorui Chen ,  Han-Yi Huang

IPC分类号： C07K16/10 ,  A61K39/42 ,  A61K39/00

CPC分类号： C07K16/10 ,  A61K39/42 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

公开(公告)号：US11377485B2

公开(公告)日：2022-07-05

申请号：US16150164

申请日：2018-10-02

申请人： Academia Sinica

发明人： Chi-Huey Wong ,  Chung-Yi Wu

IPC分类号： C07K16/18 ,  C12P21/00 ,  C07K16/28

摘要： Methods for making modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Antibodies comprising Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.

公开(公告)号：US10407673B2

公开(公告)日：2019-09-10

申请号：US16011622

申请日：2018-06-18

申请人： CHO Pharma Inc. ,  Academia Sinica

发明人： Nan-Horng Lin ,  Lin-Ya Huang ,  Sachin S Shivatare ,  Li-Tzu Chen ,  Chi-Huey Wong ,  Chung-Yi Wu ,  Ting Cheng

IPC分类号： C12N9/42 ,  C12P21/00 ,  C07K16/28

摘要： A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.